Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2003
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. The reporting period includes the full results of Immunex Corporation, acquired in July 2002, which significantly expanded Amgen's product portfolio to include ENBREL®.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sept 30, 2003 |
Nine Months Ended Sept 30, 2003 |
Nine Months Ended Sept 30, 2002 |
|---|---|---|---|
| Total Revenues | $2,207.4 | $6,009.7 | $3,756.9 |
| Net Income (Loss) | $612.1 | $1,712.6 | $(1,848.3) |
| Diluted EPS | $0.46 | $1.28 | $(1.67) |
| Operating Cash Flow | N/A | $2,369.1 | $1,428.7 |
| Cash & Marketable Securities | $5,025.0 | $5,025.0 | $4,663.9 |
| Long-Term Debt | $3,071.8 | $3,071.8 | $3,047.7 |
Margins: Cost of sales as a percentage of product sales was 16.4% for the three months ended September 30, 2003, and 16.9% for the nine-month period. The effective tax rate for the nine months ended September 30, 2003, was 28.7%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 47% for the three months and 60% for the nine months compared to the prior year periods. Product sales grew 54% (quarterly) and 67% (year-to-date), driven primarily by ENBREL®, Aranesp®, and Neulasta®.
- Profitability Turnaround: The company reported a net income of $612.1 million for the quarter, a significant improvement from a net loss of $2.6 billion in the same period in 2002. The 2002 loss was heavily impacted by a one-time $2.99 billion write-off of acquired in-process research and development (IPR&D) related to the Immunex acquisition.
- Product Performance:
- Aranesp®: Sales increased 270% (quarterly) and 390% (year-to-date) in the U.S., driven by demand for chemotherapy-induced anemia treatment.
- Neulasta®: Worldwide sales increased 131% (quarterly) and 253% (year-to-date), though U.S. NEUPOGEN® sales declined 18% year-to-date due to patient conversion to Neulasta®.
- ENBREL®: Sales increased 116% for the quarter, driven by new patient additions in rheumatology and dermatology.
- Expenses: R&D expenses increased 54% year-to-date due to higher staff costs, clinical trials, and manufacturing costs. SG&A expenses increased 38% year-to-date, largely due to higher marketing expenses and Wyeth profit share related to ENBREL® growth.
Guidance, Outlook, and Risks
- Capital Expenditures: Management estimates spending on capital projects for 2003 to be between $1.3 billion and $1.5 billion, primarily for the Rhode Island manufacturing plant, Puerto Rico expansion, and Seattle research center.
- Liquidity: The company believes existing funds and cash flow are adequate for working capital and capital expenditure needs. A $1.0 billion shelf registration statement was established in October 2003 for financial flexibility.
- Key Risks:
- Reimbursement: Sales depend on third-party payor reimbursement. A 2003 CMS rule reduced reimbursement rates for Aranesp® in hospital outpatient settings, which could impact future sales.
- Supply Constraints: ENBREL® supply is dependent on third-party manufacturers (Boehringer Ingelheim) and Amgen's Rhode Island facility. Supply interruptions could materially affect sales.
- Competition: Significant competition exists in rheumatoid arthritis (ENBREL®) and anemia (Aranesp®/EPOGEN®) markets.
- Legal Proceedings: The company settled patent litigation with Genentech in August 2003. It is also involved in Average Wholesale Price (AWP) litigation.
Investor Verification Checklist
- Reimbursement Impact: Verify the extent of the impact of the CMS reimbursement rule change on Aranesp® sales in the hospital outpatient setting.
- Supply Chain Stability: Monitor ENBREL® supply levels and the status of the Rhode Island facility and third-party manufacturing agreements to ensure no shortages.
- Product Conversion Rates: Track the rate of patient conversion from NEUPOGEN® to Neulasta® to assess the trajectory of NEUPOGEN® sales decline.
- Legal Settlements: Review the financial impact of the Genentech settlement and potential outcomes of the AWP litigation.
- Capital Allocation: Confirm the execution of the $1.3–$1.5 billion capital expenditure plan and its impact on future manufacturing capacity.